Frontier Biotechnologies Inc. (SHA:688221)

China · Delayed Price · Currency is CNY

22.07

+1.41 (6.82%)

At close: Aug 20, 2026

15.61% (1Y)

Market Cap	8.27B +15.6%
Revenue (ttm)	392.19M +194.5%
Net Income	3.46M
EPS	0.01
Shares Out	374.58M
PE Ratio	2,387.74
Forward PE	918.55
Dividend	n/a
Ex-Dividend Date	n/a

Volume	28,911,600
Open	21.57
Previous Close	20.66
Day's Range	20.89 - 22.80
52-Week Range	13.06 - 29.98
Beta	0.89
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 31, 2026

About Frontier Biotechnologies

Frontier Biotechnologies Inc., a commercial-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes various medicines that improve patients’ health in China. It offers Aikening, an IV fusion inhibitor for dual therapy of HIV-1. The company’s pipeline products include FB2004 indicated for HBV; FB7011 and FB7013 for IgA nephropathy; FB7012 to treat hyperuricemia and gout; FB7041 to treat tumors; FB7024 for the treatment of hyperlipidemia; FB7023 to treat ASCVD; FB7033 for the treatment of MASH; FB4001 for osteoporos... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 2002

Employees 314

Stock Exchange Shanghai Stock Exchange

Ticker Symbol 688221

Full Company Profile

Financial Performance

In 2025, Frontier Biotechnologies's revenue was 123.39 million, a decrease of -4.70% compared to the previous year's 129.47 million. Losses were -268.05 million, 33.1% more than in 2024.

Financial Statements